Juno Therapeutics Inc (JUNO) Releases Earnings Results, Misses Expectations By $-0.26 EPS

Juno Therapeutics Inc (JUNO) reported quarterly earnings results on Monday, May-9-2016. The company reported $-0.78 earnings per share for the quarter, missing the analyst consensus estimate by $-0.26. Analysts had a consensus of $-0.52. The company posted revenue of $9.80 million in the period, compared to analysts expectations of $3.15 million. During the same quarter in the previous year, the company posted $-0.30 EPS.

Many Wall Street Analysts have commented on Juno Therapeutics Inc. Company shares were Reiterated by Maxim Group on Apr 11, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $78 .Citigroup Initiated Juno Therapeutics Inc on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $45.Juno Therapeutics Inc was Upgraded by Guggenheim to ” Buy” on Feb 17, 2016.

Juno Therapeutics Inc closed down -0.6 points or -1.59% at $37.17 with 9,72,259 shares getting traded on Friday. Post opening the session at $37.79, the shares hit an intraday low of $36.81 and an intraday high of $39.45 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Apr 19, 2016, Richard Klausner (director) sold 12,000 shares at $43.15 per share price. According to the SEC, on Apr 19, 2016, Bernard J Cassidy (General Counsel & Secretary) sold 3,200 shares at $43.30 per share price. On Mar 30, 2016, Anthony B Evnin (director) purchased 8,000 shares at $36.58 per share price, according to the Form-4 filing with the securities and exchange commission.

Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.

Juno Therapeutics Inc

Leave a Reply

Juno Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Juno Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.